Across TCGA pan-cancer cohorts, KRTAP10-2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated KRTAP10-2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher KRTAP10-2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP10-2 expression acts as an unfavorable survival marker.

LIHC are the cancer types where KRTAP10-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.051	0.783	<.001	36	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: KRTAP10-2 tumor-vs-normal RNA expression · all KRTAP10-2 data types